Loading clinical trials...
Loading clinical trials...
Phase 1 Study of ONT-10, a Liposomal MUC1 Cancer Vaccine, in Patients With Solid Tumors
Conditions
Interventions
ONT-10
Locations
3
United States
University of Colorado Cancer Center
Aurora, Colorado, United States
Mary Crowley Cancer Research Center
Dallas, Texas, United States
Northwest Medical Specialties, PLLC
Tacoma, Washington, United States
Start Date
March 1, 2013
Primary Completion Date
May 1, 2015
Completion Date
September 1, 2015
Last Updated
May 17, 2018
NCT04570423
NCT06926283
NCT07177937
NCT07489378
NCT07181681
NCT07387068
Lead Sponsor
Cascadian Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions